Division of Endocrinology, Diabetes and Nutrition, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Boston University School of Medicine, Boston Medical Center, 670 Albany Street, Second Floor, Boston, Massachusetts 02118, USA.
J Clin Endocrinol Metab. 2010 Aug;95(8):3955-64. doi: 10.1210/jc.2010-0102. Epub 2010 Jun 9.
During testosterone (T) therapy, T is partly converted to 17beta-estradiol (E2) and 5alpha-dihydrotestosterone (DHT). Effects of age, testosterone dose, and body composition on total and free E2 and DHT levels are unknown.
We evaluated age and dose-related differences in E2 and DHT levels in response to graded doses of testosterone enanthate in young and older men.
Fifty-one young (aged 19-35 yr) and 52 older (aged 59-75 yr) men completed treatment with monthly injections of a GnRH agonist plus randomly assigned weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg) for 5 months.
During testosterone administration, total and free E2 levels increased dose-dependently (dose effect, P<0.001) in both young and older men. Total and free E2 levels and E2:T ratios during T administration were higher in older than young men, but age-related differences in free E2 and free E2:T ratios were not significant after adjusting for testosterone levels, percentage fat mass, and SHBG. DHT levels and DHT:T ratios were dose-related but did not differ between young and older men. Mechanistic modeling of free hormone data revealed that the conversions of T to E2 and DHT were both consistent with saturable Michaelis-Menten kinetics. The in vivo Km values were estimated to be 1.83 nm for aromatase and 3.35 nm for 5alpha-reductase, independent of age. The Vmax parameter for E2 was 40% higher in older men than younger men, but Vmax for DHT was not significantly different between age groups.
During im testosterone administration, E2 and DHT levels exhibit saturable increases with dose. The rate of whole body aromatization is higher in older men, partly related to their higher percentage fat mass, SHBG, and testosterone levels.
在睾酮(T)治疗期间,T 部分转化为 17β-雌二醇(E2)和 5α-二氢睾酮(DHT)。年龄、睾酮剂量和身体成分对总游离 E2 和 DHT 水平的影响尚不清楚。
我们评估了年龄和剂量相关的差异,以响应年轻和老年男性接受不同剂量的庚酸睾酮治疗。
51 名年轻(年龄 19-35 岁)和 52 名老年(年龄 59-75 岁)男性完成了每月注射 GnRH 激动剂和随机分配的每周剂量庚酸睾酮(25、50、125、300 或 600mg)的治疗,共 5 个月。
在睾酮给药期间,总游离 E2 水平呈剂量依赖性增加(剂量效应,P<0.001),在年轻和老年男性中均如此。总游离 E2 水平和 E2:T 比值在老年男性中高于年轻男性,但在调整睾酮水平、体脂百分比和 SHBG 后,游离 E2 和游离 E2:T 比值的年龄相关差异不显著。DHT 水平和 DHT:T 比值与剂量有关,但在年轻和老年男性之间无差异。游离激素数据的机制建模表明,T 向 E2 和 DHT 的转化均符合饱和米氏动力学。体内 Km 值估计为芳香酶 1.83nm 和 5α-还原酶 3.35nm,与年龄无关。E2 的 Vmax 参数在老年男性中比年轻男性高 40%,但 DHT 的 Vmax 在年龄组之间无显著差异。
在男性接受外源性睾酮治疗期间,E2 和 DHT 水平随剂量呈饱和增加。老年男性的全身芳香化作用率较高,部分原因是他们的体脂百分比、SHBG 和睾酮水平较高。